4.8 Article

Vasodilator-Stimulated Phosphoprotein Promotes Activation of Hepatic Stellate Cells by Regulating Rab11-Dependent Plasma Membrane Targeting of Transforming Growth Factor Beta Receptors

期刊

HEPATOLOGY
卷 61, 期 1, 页码 361-374

出版社

WILEY-BLACKWELL
DOI: 10.1002/hep.27251

关键词

-

资金

  1. NCATS NIH HHS [UL1 TR000135] Funding Source: Medline
  2. NCI NIH HHS [P30 CA015083, R01 CA160069] Funding Source: Medline
  3. NIAAA NIH HHS [AA021171, R01 AA021171] Funding Source: Medline
  4. NIDDK NIH HHS [P30 DK084567, R01 DK059615, P30DK084567] Funding Source: Medline

向作者/读者索取更多资源

Liver microenvironment is a critical determinant for development and progression of liver metastasis. Under transforming growth factor beta (TGF-) stimulation, hepatic stellate cells (HSCs), which are liver-specific pericytes, transdifferentiate into tumor-associated myofibroblasts that promote tumor implantation (TI) and growth in the liver. However, the regulation of this HSC activation process remains poorly understood. In this study, we tested whether vasodilator-stimulated phosphoprotein (VASP) of HSCs regulated the TGF--mediated HSC activation process and tumor growth. In both an experimental liver metastasis mouse model and cancer patients, colorectal cancer cells reaching liver sinusoids induced up-regulation of VASP and alpha-smooth muscle actin (-SMA) in adjacent HSCs. VASP knockdown in HSCs inhibited TGF--mediated myofibroblastic activation of HSCs, TI, and growth in mice. Mechanistically, VASP formed protein complexes with TGF- receptor II (TRII) and Rab11, a Ras-like small GTPase and key regulator of recycling endosomes. VASP knockdown impaired Rab11 activity and Rab11-dependent targeting of TRII to the plasma membrane, thereby desensitizing HSCs to TGF-1 stimulation. Conclusions: Our study demonstrates a requirement of VASP for TGF--mediated HSC activation in the tumor microenvironment by regulating Rab11-dependent recycling of TRII to the plasma membrane. VASP and its effector, Rab11, in the tumor microenvironment thus present therapeutic targets for reducing TI and metastatic growth in the liver. (Hepatology 2015;61:361-374)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据